GlaxoSmithKline (LON:GSK) Given a GBX 1,900 Price Target at Bank of America
Bank of America set a GBX 1,900 ($24.83) price objective on GlaxoSmithKline (LON:GSK) in a research report released on Friday, Borsen Zeitung reports. The firm currently has a neutral rating on the stock.
Several other equities analysts have also weighed in on the stock. Liberum Capital restated a hold rating on shares of GlaxoSmithKline in a report on Friday, August 23rd. Jefferies Financial Group restated a buy rating on shares of GlaxoSmithKline in a report on Thursday, August 29th. Goldman Sachs Group set a GBX 1,900 ($24.83) target price on shares of GlaxoSmithKline and gave the stock a buy rating in a report on Friday, August 23rd. Deutsche Bank increased their target price on shares of GlaxoSmithKline from GBX 1,620 ($21.17) to GBX 1,645 ($21.49) and gave the stock a hold rating in a report on Monday, September 2nd. Finally, HSBC set a GBX 2,110 ($27.57) target price on shares of GlaxoSmithKline and gave the stock a buy rating in a report on Tuesday, September 10th. One investment analyst has rated the stock with a sell rating, twelve have given a hold rating and three have given a buy rating to the company’s stock. The stock presently has an average rating of Hold and an average price target of GBX 1,701.79 ($22.24).
Shares of LON GSK opened at GBX 1,627.20 ($21.26) on Friday. The company’s 50 day simple moving average is GBX 1,680.18 and its 200 day simple moving average is GBX 1,592.76. GlaxoSmithKline has a fifty-two week low of GBX 1,408.80 ($18.41) and a fifty-two week high of GBX 1,767 ($23.09). The firm has a market capitalization of $81.17 billion and a P/E ratio of 18.32. The company has a debt-to-equity ratio of 1,127.74, a current ratio of 0.71 and a quick ratio of 0.44.
In related news, insider Vivienne Cox acquired 434 shares of the stock in a transaction dated Wednesday, July 24th. The stock was bought at an average price of GBX 1,654 ($21.61) per share, with a total value of £7,178.36 ($9,379.80). Insiders have bought 457 shares of company stock valued at $755,906 in the last three months.
GlaxoSmithKline Company Profile
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.
Recommended Story: Outperform Rating
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.